The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
Charles D Burger
Pulmonary circulation, 2017
View PDFchevron_right
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
Werner Seeger
The Journal of Heart and Lung Transplantation, 2011
View PDFchevron_right
Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension
Charles D Burger
Therapeutic Advances in Chronic Disease, 2018
View PDFchevron_right
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study
Gisela Martina Bohns Meyer
American Journal of Respiratory and Critical Care Medicine
View PDFchevron_right
Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
Jeremy Feldman
Pulmonary Circulation, 2020
View PDFchevron_right
Inhaled treprostinil sodium for pulmonary hypertension
Richard A Krasuski
View PDFchevron_right
BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
Jinesh Mehta
Pulmonary Circulation, 2022
View PDFchevron_right
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial
Keyur Parikh
Circulation, 2013
View PDFchevron_right
Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension
Ioana Preston, Nicholas Hill, Jeremy Feldman, Charles D Burger
Pulmonary circulation, 2014
View PDFchevron_right
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension
Keyur Parikh
Circulation, 2013
View PDFchevron_right
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
Werner Seeger
Journal of the American College of Cardiology, 2010
View PDFchevron_right
Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
George Sokos, Amresh Raina
Pulmonary Circulation, 2013
View PDFchevron_right
sj-pdf-1-pul-10.1177_2045894019866335 - Supplemental material for Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
Roblee Allen
2020
View PDFchevron_right
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Roblee Allen
New England Journal of Medicine
View PDFchevron_right
Treprostinil in the treatment of pulmonary arterial hypertension
Jade Fann
Future Cardiology, 2020
View PDFchevron_right
Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation
Jeremy Feldman
Pulmonary Circulation, 2017
View PDFchevron_right
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease in the INCREASE Trial
Jinesh Mehta
A6. A006 HOT TAKES FROM CLINICAL TRIALS IN LUNG DISEASE, 2021
View PDFchevron_right
Current and Emerging Therapies in Pulmonary Arterial Hypertension: Focus on Treprostinil
Melvyn Rubenfire
Clinical Medicine Reviews in Vascular Health, 2011
View PDFchevron_right
Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension
Johannes Jakowitsch
The Journal of Heart and Lung Transplantation, 2012
View PDFchevron_right
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
Jeremy Feldman
European Respiratory Journal
View PDFchevron_right
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial
Fabian Diez
American Journal of Respiratory and Critical Care Medicine, 2019
View PDFchevron_right
EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
Sonja Bartolome
Pulmonary Circulation
View PDFchevron_right
Effectiveness and Safety of Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Children
Usha Krishnan
The American Journal of Cardiology, 2012
View PDFchevron_right
Transition from parenteral to oral treprostinil in pulmonary arterial hypertension
Jeremy Feldman
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2016
View PDFchevron_right
Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center
Sonja Bartolome
Pulmonary Circulation, 2015
View PDFchevron_right
Long-term effect of subcutaneous treprostinil in patients with pulmonary hypertension: rationale and design of the phase IV, multicentre, observational TREPAR-HP study
Adrián Lescano
International Journal of Clinical Trials
View PDFchevron_right